NewsRoom Articles - Page 53 of 55

MondayJun 27, 2022 2:15 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substanceKernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeuticsTechnology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that preliminary data…

MondayJun 27, 2022 12:00 pm

Cepton, Inc. (NASDAQ: CPTN), a Leader in Lidar, Continues to Execute on its Core Strategic Milestones Across Automotive & Smart Infrastructure

Cepton develops lidar sensors for ADAS and autonomous driving, and has been awarded the largest lidar production contract to date with products set to debut next year across General Motor’s Ultra Cruise ADAS platformAward covers 4 target vehicle models in 2023, 4+ models in 2024, and an anticipated 4+ models in 2025 with Cadillac being the first to introduce the Ultra Cruise technologyCepton’s proprietary MMT(R) technology provides a highly competitive price for performance and reliabilityFounder-led, visionary management team with substantial “skin in the game” Since becoming public in early 2022, Cepton (NASDAQ: CPTN) has not deviated from its plan to…

MondayJun 27, 2022 11:15 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Grows Quarterly Net Income by Over 359% Yoy, Sees Margins Widen by Nearly 43%

Golden Matrix Group recently reported its 15th consecutive quarter of profitabilityGMGI’s second quarter revenues rose 221% YoY with net income expanding by upwards of 359% YoYGMGI attributed the rise in revenues to the added contribution from UK-based competition company, RKingsCompetitions Ltd, which Golden Matrix acquired in November 2021Management expressed their continued optimism on GMGI’s future prospects, with the company’s B2B and B2C verticals both showing robust growth Fifteen consecutive quarters of profitability is a remarkable feat; even Amazon, the world's largest e-commerce operator, reported a net loss over the past three months. Moreover, Golden Matrix Group (NASDAQ: GMGI), a developer…

MondayJun 27, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needsThe company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria's own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery Lexaria also recently announced an…

FridayJun 24, 2022 12:00 pm

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinatedThe AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herdNo additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus countsThe reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking The COVID-19…

FridayJun 24, 2022 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Authorizes the Repurchase of up to $5 Million Shares

Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common sharesLuis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expensesAt the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million Flora Growth (NASDAQ: FLGC) is a global leader in the cultivation, marketing, and distribution of premium-quality cannabis products and brands at below-market prices. Flora Growth recently announced that the company’s Board of Directors (the "Board") has authorized the repurchase…

ThursdayJun 23, 2022 10:30 am

Golden Matrix Group Inc.’s (NASDAQ: GMGI) AI-Powered I-Gaming Systems Fuel Revenue Growth Despite Looming Recession

Online gambling growing despite recession fears, expected to reach $115.13 billion by 2026 at CAGR of 9.2% GMGI leads industry with modular, turnkey, and white label gaming platforms compatible with all major browsers, operating systems, devicesGM-X gaming systems collect player data, leverage AI algorithms to enhance gaming experience, increase player retention, boost B2B client profitability Online gambling continues to grow globally and is expected to reach $81.08 billion in 2022 at a compound annual growth rate (“CAGR”) of 10.4% (https://ibn.fm/CqiDg). Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, leads the industry with…

ThursdayJun 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD productsValcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in EuropeAnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this…

WednesdayJun 22, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Closes the First Half of 2022 with UK Product Launch, Successful Brand Acquisition, and a Collaboration with Ricky Williams’ Cannabis Brand, Highsman

Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharingThe company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis researchFlora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe The first half of 2022 has been successful for Flora Growth (NASDAQ: FLGC). At the beginning of the year, the company’s management noted how the cannabis sector was ripe for the picking. They noted how great brands and cost advantages are optimal traits for…

TuesdayJun 21, 2022 9:45 am

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditionsLexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000